Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.

Ioannis PoziosNina N SeelNina A HeringLisa HartmannVerena LiuPeter CamajMario H MüllerLucas D LeeChristiane J BrunsMartin E KreisHendrik Seeliger

Published in: Cellular oncology (Dordrecht) (2020)

Inhibition of ERβ and the IL-6/gp130/STAT3 signaling pathway by raloxifene leads to potent reduction of PDAC growth in vitro and in vivo. Our results suggest that ERβ signaling and IL-6/gp130 interaction may serve as promising drug targets for pancreatic cancer and that raloxifene may serve as an attractive therapeutic option for PDAC patients expressing the ERβ isotype.

Keyphrases

endoplasmic reticulum
estrogen receptor
breast cancer cells
signaling pathway
end stage renal disease
cell proliferation
newly diagnosed
chronic kidney disease
prognostic factors
pi k akt
drug induced
endoplasmic reticulum stress